This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Invacare Corporation
11/8/2022
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Invercare third quarter 2022 conference call and webcast. After the management overview, we will open the call to questions. Investors and analysts interested in asking questions will need to dial in as questions cannot be submitted by the webcast. For the first part of the call, all phone lines have been placed on mute. This conference is being recorded Tuesday, November 8th, 2022. I will now hand over to Lois Lee, Invocare's Director of Treasury and Investor Relations.
Thank you. Joining me on today's call from Invocare are Jeff Pertil, Interim President and Chief Executive Officer, and Kathy Lenahan, Senior Vice President and Chief Financial Officer. Today, we will be reviewing our third quarter 2022 financial results and providing investors with an update on our business outlook. To help investors follow along, we have created slides to accompany this webcast. For those dialing in, you can find a link to our webcast slide presentation in the at global.invacare.com slash investor dash relations. Further information can be found in our SEC filings. Before Jeff begins, I'd like to note that during today's call, we may make forward-looking statements about the company that by their nature address matters that are uncertain. Actual future results may differ materially from those expressed in our statements today due to various uncertainties, and I refer you to the cautionary statement included on the second page of our webcast slides and in our third quarter earnings release. For an explanation of the items discussed on today's calls that are considered to be non-GAAP financial information, such as constant currency net sales, constant currency SG&A expense, free cash flow, and adjusted EBITDA, please see the notes in the appendix of our webcast slides and in the related reconciliations in the slides and the earnings release posted to our website. I will now turn the call over to Jeff Purtill.
Thank you, Lois, and good morning, everyone. Before we begin, I'd like to say how pleased I am to be here this morning. While I'm new to the CEO role, I have been with Invercare for over 12 years in various roles of increasing responsibilities, and I am very familiar with our products, customers, and the markets. I have enjoyed traveling around the organization and meeting as many associates as possible, and I want to thank them for all of their hard work. I wholeheartedly believe that Invercare has a central role to play in improving the quality of life for our end users by providing home healthcare solutions that make life's experiences possible. Just over two months ago, I was named interim president and CEO. Since then, the company has acted on various strategic initiatives to strengthen the business and return to profitability. I am excited about the many opportunities ahead to further optimize the business performance. As you can see on slide three, in late July and early October, we increased our financial flexibility by securing $85 million of additional financing, a portion of which was used to unlock the supply chain. As Cathy will explain in more detail later, third quarter revenues were impacted by supply chain challenges and component shortages due to supplier delivery holds, which have since improved. Early in the fourth quarter, we have already seen the benefit of this additional liquidity and expect to deliver sequential growth in our key metrics for the full quarter. We continue to work hard to regain the confidence of our customers and the trust of our vendors as we navigate through these challenges. Turning to our transformation plan, we have spent the better part of the year taking a hard look at every aspect of our business, leaving no stone unturned as we position Invercare for the future. After carefully evaluating our strategic options and core revenue streams, we have determined that the lifestyle and mobility and seeding product categories, which have experienced 30% more open orders since the end of last year, are core to improving Invercare's growth and profitability. As a result, we are discontinuing production of respiratory products by the end of the year. We will continue to support the respiratory parts and services needs of our customers and honour our respiratory-related warranty and regulatory obligations. As previously guided, sales of respiratory products are anticipated to decline further given excess supply in the market and lower COVID-related demand. Combined with higher input costs and inflationary pressures, respiratory products no longer meet our minimum profitability targets. Turning to our board. we have added three new directors who have deep expertise in business turnarounds. We look forward to working closely with our full board as we continue to navigate through our transformation. In summary, we are committed to taking necessary and decisive action to accelerate the execution of our multifaceted strategic plan and increase shareholder value. We have made great progress in just a few months' time, as the actions we have taken so far are already driving sequential revenue and profitability improvements in early fourth quarter. Turning to slide four, as I mentioned earlier, we are updating our strategic priorities to focus our resources on those categories which have the highest potential. Our core product categories of lifestyle and mobility and seating continue to experience strong demand and orders. These products serve a growing market with favourable demographics and reduces the complexity of the supply chain overall. Our fully refreshed line of award-winning products are driving great customer interest and deliver important end-user benefits. We anticipate that by streamlining operations to focus on our core categories, we will improve product mix, expand gross margin, reduce our costs to serve, and ultimately drive higher profitability and increase shareholder value. I will now turn the call over to Kathy, who will provide a more detailed financial summary.
You're reading a preview of the IVC Q3 2022 earnings call.
Free account.